Go To Main content

Historic development of Department of Nuclear Medicine

 

      The Department of Nuclear Medicine was established in 1972. Professor Shin- Hwa Yeh, a pioneer of Nuclear Medicine in Taiwan, was the first to be a director of the department. Initially, there were 15 staffs and 2 liner scanner for imaging in the department. Only bone, liver and spleen, brain and thyroid gland scintigraphy could be performed. Up to now, there are 34 staffs, 5 angular γ-camera, one scanner of positron emission tomography (PET) and one set of cyclotron in the department. Thirty-one items of imaging and 28 items of radioimmunoassay (RIA) can be done routinely. In addition, there are 3 special wards for management the patients with residual or recurrent thyroid carcinoma. The following is a list of milestones in the development of the Department of Nuclear Medicine since 1972.

1972: Nuclear Medicine Center is set up; the director is Professor Shin-Hwa Yeh.

1973: Bone, brain (Tc-99m), liver and spleen and thyroid gland scintigraphy are applied for clinical use.

1973~1975: RIA for detection the titers of hepatitis B markers, thyroid hormones, α-FP and CEA are applied for clinical use.

1975: Dr. Keh-Chi Chen becomes a director of the center.

1977: Dr. Yeon-Biing Lee takes office the director of the center.

1979: Nuclear Medicine Center reorganizes as the Department of Nuclear Medicine; Professor Shin-Hwa Yeh is the director.

1980: I-131 thyroid ablation therapy is applied for clinical use.

1982: Dr. William Chen becomes a director of the Department of Nuclear Medicine; the first angular γ-camera is purchased; renal and lung perfusion scintigraphy are applied for clinical use.

1983: Tl-201 myocardial perfusion scintigraphy is applied for clinical use.

1986: The first-pass radionuclide angiography and equilibrium radionuclide angiography are applied for clinical use.

1987: Tc-99m HMPAO brain scan is applied for clinical use.

1987~1990: RIA for detection the titers of tumor markers including CA153, CA125, CA199, SCC, Vit B12 and ferretin are applied for clinical use.

1990: Lung ventilation scan with Xe-133 is applied for clinical use.

1991: RIA for detection the titers of PSA and PAP are applied for clinical use.

1995: Dr. William Chen becomes the chairman of the Society of Nuclear Medicine of R.O.C.

1996: The first combine conference of Nuclear Medicine between China Continent and Taiwan is held in Taipei; Dr. William Chen is the chairman.

1998: Dr. Wen-Shen Huang becomes a director of the department.

1999: Tc-99m MIBI myocardial perfusion scintigraphy is applied for clinical use.

2000: Tc-99m Trodat-1 brain scan is applied for clinical use; RIA for detection the titers of β2 microglobulin and Ach-R Ab are applied for clinical use.

2001: The Department of Nuclear Medicine is moved to Nei-Hu; a SPECT/CT γ-camera is purchased.

2002: I-123 ADAM brain scan is applied for animal study.

2003: Dr. Cheng-Yi Cheng becomes a director of the department; PET center is found.

2005: We became the first hospital approval for manufacturing F-18 FDG in Taiwan

2006: We cooperated with several medical centers in Taiwan and the world; we also held the 6th cyclotron club together with Tzu-Chi hospital.

2006: Established the PACS system and used the digital image for interpretation.

2006: We invented the F-18 FADAM and host the first human clinical trial of F-18 FADAM in the world.

2007: We hosted the international symposium of radiation accident, invited several scholars from Japan and Korea to discuss the issue of radiation protection.

2007: We run the annual maneuver of radiation accident with Tai-power nuclear power plant and the result is a real success.

2008: We signed a memorandum of agreement in communication and cooperation with National Institute of Radiological Sciences (NIRS) of Japan and Korea Institute of Radiological and Medical Sciences (KIRAMS) of Korea.

2009: We run the annual maneuver of radiation accident with Tai-power nuclear power plant and the result is a real success.

2014: Dr. Cheng-Yi Cheng becomes the chairman of the Society of Nuclear Medicine of R.O.C.

2014:Discovery PET/CT 710 system is purchase and applied for clinical used.

2016:Discovery SPET/CT 670 system is purchase and applied for clinical used.

2016:Discovery SPET 530NM system is purchase and applied for clinical used.

2017:Win the National Innovation Award.

 

The basic principle & clinical application in nuclear medicine

Nuclear medicine is defined quite simply as the use of radiopharmaceuticals to show the status of body physiology & biochemistry. Owing to the great promotion of medical knowledge, pharmacological manufacture, & instrumental technology in recent years, besides the traditional functional imaging, nuclear medicine now could provide more accurate anatomic relationship of disease, especially after the new scanner consisted with CT function was vended.

      In our hospital, there are two major jobs of nuclear medicine, including radioimmune assay and radiopharmaceutical scintigraphy. Radioimmune assay could evaluate some special metabolites or hormone in kinds of body fluid, and radiopharmaceutical scintigraphy could provide visible information of body status with injected very few amount of radiotracer. In basically, the examinations of nuclear medicine are non-invasive, painless and safe diagnostic tool for most of population. It should be more careful to do or avoiding our examination for pregnant women & planning to have pregnancy because of the radiosensitivity to fetus & little child.

       The current nuclear medicine could provide the clinical diagnostic information in neurology, cardiovascular system, respiratory system, digestive system, genitourinary system, endocrine system and musculoskeletal system....etc. Because of the more early change in functional status than anatomic structure in a disease, the examination of nuclear medicine could provide a chance to early intervene, monitor & evaluate the disease.

 

 

 

text-to-speech
Views:3908 UpdateDate:2019-09-17T15:50:20
::: fat footer switch
Web Priority AA Accessibility Approval_image
Web Priority AA Accessibility Approval_image
Republic of China (Taiwan) Govemment Entry Point_image